Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency.
Gálvez BG, Covarello D, Tolorenzi R, Brunelli S, Dellavalle A, Crippa S, Mohammed SA, Scialla L, Cuccovillo I, Molla F, Staszewsky L, Maisano F, Sampaolesi M, Latini R, Cossu G. Gálvez BG, et al. Among authors: latini r. Cardiovasc Res. 2009 Sep 1;83(4):707-16. doi: 10.1093/cvr/cvp159. Epub 2009 May 20. Cardiovasc Res. 2009. PMID: 19457891 Free article.
Valsartan for the treatment of heart failure.
Latini R, Masson S, Staszewsky L, Maggioni AP. Latini R, et al. Expert Opin Pharmacother. 2004 Jan;5(1):181-93. doi: 10.1517/14656566.5.1.181. Expert Opin Pharmacother. 2004. PMID: 14680446 Review.
Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats.
Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi P, Latini R. Fiordaliso F, et al. Among authors: latini r. J Mol Cell Cardiol. 2004 Nov;37(5):959-68. doi: 10.1016/j.yjmcc.2004.07.008. J Mol Cell Cardiol. 2004. PMID: 15522273
Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: a comparison with bone marrow progenitors, fibroblasts, and endothelial cells.
Galli D, Innocenzi A, Staszewsky L, Zanetta L, Sampaolesi M, Bai A, Martinoli E, Carlo E, Balconi G, Fiordaliso F, Chimenti S, Cusella G, Dejana E, Cossu G, Latini R. Galli D, et al. Among authors: latini r. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):692-7. doi: 10.1161/01.ATV.0000156402.52029.ce. Epub 2005 Jan 20. Arterioscler Thromb Vasc Biol. 2005. PMID: 15662021
A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.
Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. Fiordaliso F, et al. Among authors: latini r. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2046-51. doi: 10.1073/pnas.0409329102. Epub 2005 Jan 25. Proc Natl Acad Sci U S A. 2005. PMID: 15671158 Free PMC article.
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators. Disertori M, et al. Among authors: latini r. J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38. doi: 10.2459/01.JCM.0000199778.85343.08. J Cardiovasc Med (Hagerstown). 2006. PMID: 16645357 Clinical Trial.
536 results